Of note, this segregation was not driven by diagnostic certainty or treatment as the proportion of therapy-naïve patients was very similar in CIDP (59.1 % group A vs. 60% group B; chi-squared p = 1) and in GBS patients (57.1% group A vs. 58.3% group B; chi-squared p = 0.98) (Figure 5B). This evidence concerns the gene PMP22 and Guillain-Barre syndrome.